GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...
Online master’s degrees in engineering and education from Purdue again rank among the nation’s finest. Four of Pur ...
Eli Lilly and Company will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the investment ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...
According to Evaluate Pharma, China's growing influence in pharmaceutical R&D is a key theme to watch in 2025. The pharma ...
The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...
Consumer Electronics Show (CES) 2025 revolved around AI ... Here is what the fund said “Alphabet Inc., Eli Lilly and Company, ...